利用肿瘤标志物基因变异提高DUPAN-2和碳水化合物抗原19-9对胰腺癌的诊断准确性
该研究采用训练/验证设计,在938例来自约翰霍普金斯医院的个体中检测FUT2/FUT3基因型,并按功能分组制定DUPAN-2和CA19-9的参考范围。结果显示,按FUT功能组个体化cutoff可提高早期胰腺癌的诊断敏感性,联合FUT/CA19-9与FUT/DUPAN-2检测对I/II期胰腺癌的敏感性达78.4%,特异性97.7%。
要点
- 按FUT3/FUT2功能组个体化DUPAN-2 cutoff,验证集中I/II期PDAC敏感性60.4% vs 统一cutoff 39.8%。
- 联合FUT/CA19-9与FUT/DUPAN-2检测,I/II期PDAC敏感性78.4%、特异性97.7%。
- 模拟CAPS队列中,FUT/CA19-9/DUPAN-2的AUCPR为0.84,高于CA19-9单检的0.51。
核心结论
- 使用肿瘤标志物基因检测个体化CA19-9和DUPAN-2参考范围,对I/II期胰腺癌取得高诊断性能。
研究设计与样本
- 训练/验证研究设计,在约翰霍普金斯医院938例个体中检测FUT2/FUT3基因型,包括607例胰腺无异常的CAPS研究受试者和331例胰腺导管腺癌(PDAC)患者。
- 采用免疫分析法测定血清DUPAN-2和CA19-9水平。
主要发现
- 在对照中识别出三个FUT功能组,其DUPAN-2水平存在显著差异:FUT3完整组、FUT3缺失/FUT2完整组和FUT3缺失/FUT2缺失组。
- 验证集中,按FUT组制定的DUPAN-2诊断cutoff对I/II期PDAC的敏感性为60.4%(95% CI,50.2至70.0),高于统一cutoff的39.8%(30.0至49.8),特异性约为99%(96.7至99.6)。
- 联合FUT/CA19-9与FUT/DUPAN-2检测对I/II期PDAC的敏感性为78.4%(72.3至83.7),特异性为97.7%(95.3至99.1),AUC更高(I/II期:0.960 vs 未加FUT检测的CA19-9+DUPAN-2的0.935;P < .001)。
- 对I期PDAC,联合检测的敏感性为62.0%(49.1至73.2;AUC,0.919 vs 0.883;P = .03)。
- FUT3缺失/FUT2缺失的PDAC患者CA19-9水平高于FUT3缺失/FUT2完整患者(中位数/IQR;24.9/57.4 vs <1/2.3 U/mL;P = .0044)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Circulating carbohydrate antigen 19-9 (CA19-9) levels reflect FUT3 and FUT2 fucosyltransferase activity. Measuring the related glycan, DUPAN-2, can be useful in individuals unable to synthesize CA19-9. We hypothesized that similar to CA19-9, FUT functional groups determined by variants in FUT3 and FUT2 influence DUPAN-2 levels, and having tumor marker reference ranges for each functional group would improve diagnostic performance. MATERIALS AND METHODS: Using a training/validation study design, FUT2/FUT3 genotypes were determined in 938 individuals from Johns Hopkins Hospital: 607 Cancer of the Pancreas Screening (CAPS) study subjects with unremarkable pancreata and 331 with pancreatic ductal adenocarcinoma (PDAC). Serum DUPAN-2 and CA19-9 levels were measured by immunoassay. RESULTS: In controls, three functional FUT groups were identified with significant differences in DUPAN-2 levels: FUT3-intact, FUT3-null/FUT2-intact, and FUT3-null/FUT2-null. DUPAN-2 training set diagnostic cutoffs for each FUT group yielded higher diagnostic sensitivity in the validation set for patients with stage I/II PDAC than uniform cutoffs (60.4% [95% CI, 50.2 to 70.0] v 39.8% [30.0 to 49.8]), at approximately 99% (96.7 to 99.6) specificity. Combining FUT/CA19-9 and FUT/DUPAN-2 tests yielded 78.4% (72.3 to 83.7) sensitivity for stage I/II PDAC, at 97.7% (95.3 to 99.1) specificity in the combined sets, with higher AUC (stage I/II: 0.960 v 0.935 for CA19-9 + DUPAN-2 without the FUT test; P < .001); for stage I PDAC, sensitivity was 62.0% (49.1 to 73.2; AUC, 0.919 v 0.883; P = .03). CA19-9 levels in FUT3-null/FUT2-null PDAC subjects were higher than in FUT3-null/FUT2-intact subjects (median/IQR; 24.9/57.4 v <1/2.3 U/mL; P = .0044). In a simulated CAPS cohort, AUC precision recall (AUCPR) scores were 0.51 for CA19-9 alone, 0.64 for FUT/CA19-9, 0.73 for CA19-9/DUPAN-2, and 0.84 for FUT/CA19-9/DUPAN-2. CONCLUSION: Using a tumor marker gene test to individualize CA19-9 and DUPAN-2 reference ranges achieves high diagnostic performance for stage I/II pancreatic cancer.
引用
- Ando Y, Dbouk M, Yoshida T, et al. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. J Clin Oncol. 2024. PMID: 38457748. doi:10.1200/JCO.23.01573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。